Immunicum released today its Q119 results, posting net loss at SEK29.1m and EPS at a negative SEK0.3 compared with negative SEK0.6 in Q118. In the period, the company started to treat the first patient in the Phase Ib/II ILIAD clinical trial.
The trial will evaluate the safety and efficacy of Immunicum’s lead product in development, ilixadencel (an allogeneic cell-based anticancer immune primer for intratumoral administration), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer. Immunicum has also published results of its Phase I/II clinical trial in hepatocellular carcinoma.
The company highlights that it is preparing for important near-term milestones which will be aimed at validating further potential of ilixadencel. According to Immunicum, this will be supported by SEK351m raised by the company in the capital increase completed recently.
Carlos de Sousa, Immunicum’s CEO, commented that „Throughout the rest of the year, our central focus will remain on the upcoming data announcements from our clinical trials which include the global Phase II MERECA study in metastatic renal cell carcinoma and the Phase I/ II study in gastrointestinal stromal tumors (GIST). We also aim to provide an update from the recently initiated Phase Ib/II ILIAD study in head and neck cancer, non-small cell lung cancer and gastric and gastroesophageal junction adenocarcinoma.”